International symposium on RNA Interference: “RNAi – Reaching for therapy”
25 October 2006 - 25 October 2006
Austria
OBJECTIVE
The objective of the RIGHT symposium is to present different findings in research on RNAi in vivo application and therapeutic approaches and to discuss novel strategies to diagnose and successfully treat severe unvanquished diseases. The symposium will include presentations from RIGHT partners and other top external researchers in the RNAi field.
PRESENTATIONS
“Using expressed sequences that induce RNA interference to counter hepatitis B virus replication in vivo”
Patrick Arbuthnot (University of Witwatersrand, South Africa)
“miRNAs and mammalian cell proliferation/ differentiation in granulocytes”
Irene Bozzoni (Università degli Studi di Roma “La Sapienza”, Italy)
“miRNAs and mammalian cell proliferation/ differentiation in muscle cells”
Annick Harel-Bellan (IAL CNRS, Villejuif, France)
“Studying autoimmunity by in vivo RNA interference”
Stephan Kissler (MIT, Cambridge, USA)
“Novel strategies in siRNA design and delivery”
Jørgen Kjems (University of Aarhus, Denmark) and
Jesper Wengel (University of Southern Denmark, Odense, Denmark)
“Conditional Mutagenesis in the Mouse Brain through RNAi”
Ralf Kühn (GSF, Neuherberg, Germany)
“Exploiting microRNA regulation to improve the efficacy and safety of gene therapy”
Luigi Naldini (Fondazione Centro San Raffaele del Monte Tabor, Milano, Italy)
“Lentiviral Vector and Adeno-associated Vector-based therapy for Motoneuron disease through RNA interference”
Cédric Raoul (Swiss Federal institute of Technology EOFL, Lausanne, Switzerland)
“Therapeutic potential of RNAi in metabolic diseases”
Christina Rondinone (Hoffman-La Roche, Nutley, USA)
“Safety and efficacy issues of retroviral stem cell gene transfer for inherited diseases: introduction to the Consert project”
Gerard Wagemaker (Erasmus University Rotterdam, the Netherlands)
The symposium is co-sponsored by Invitrogen, Qiagen, Ambion, Beckman Coulter, Dharmacon and Amaxa.
WHAT IS RIGHT?
RIGHT stands for RNA Interference Technology as Human Therapeutic tool. It is a research project supported by the European Commission’s Sixth Framework Programme with a duration of 4 years. The project brings together 22 research institutes, universities and companies and aims at exploiting and further developing the vast potential of RNAi to provide effective therapeutic tools for the treatment of severe diseases.
For further information and registration, please visit: http://www.ip-right.org(opens in new window)
The objective of the RIGHT symposium is to present different findings in research on RNAi in vivo application and therapeutic approaches and to discuss novel strategies to diagnose and successfully treat severe unvanquished diseases. The symposium will include presentations from RIGHT partners and other top external researchers in the RNAi field.
PRESENTATIONS
“Using expressed sequences that induce RNA interference to counter hepatitis B virus replication in vivo”
Patrick Arbuthnot (University of Witwatersrand, South Africa)
“miRNAs and mammalian cell proliferation/ differentiation in granulocytes”
Irene Bozzoni (Università degli Studi di Roma “La Sapienza”, Italy)
“miRNAs and mammalian cell proliferation/ differentiation in muscle cells”
Annick Harel-Bellan (IAL CNRS, Villejuif, France)
“Studying autoimmunity by in vivo RNA interference”
Stephan Kissler (MIT, Cambridge, USA)
“Novel strategies in siRNA design and delivery”
Jørgen Kjems (University of Aarhus, Denmark) and
Jesper Wengel (University of Southern Denmark, Odense, Denmark)
“Conditional Mutagenesis in the Mouse Brain through RNAi”
Ralf Kühn (GSF, Neuherberg, Germany)
“Exploiting microRNA regulation to improve the efficacy and safety of gene therapy”
Luigi Naldini (Fondazione Centro San Raffaele del Monte Tabor, Milano, Italy)
“Lentiviral Vector and Adeno-associated Vector-based therapy for Motoneuron disease through RNA interference”
Cédric Raoul (Swiss Federal institute of Technology EOFL, Lausanne, Switzerland)
“Therapeutic potential of RNAi in metabolic diseases”
Christina Rondinone (Hoffman-La Roche, Nutley, USA)
“Safety and efficacy issues of retroviral stem cell gene transfer for inherited diseases: introduction to the Consert project”
Gerard Wagemaker (Erasmus University Rotterdam, the Netherlands)
The symposium is co-sponsored by Invitrogen, Qiagen, Ambion, Beckman Coulter, Dharmacon and Amaxa.
WHAT IS RIGHT?
RIGHT stands for RNA Interference Technology as Human Therapeutic tool. It is a research project supported by the European Commission’s Sixth Framework Programme with a duration of 4 years. The project brings together 22 research institutes, universities and companies and aims at exploiting and further developing the vast potential of RNAi to provide effective therapeutic tools for the treatment of severe diseases.
For further information and registration, please visit: http://www.ip-right.org(opens in new window)